Karyopharm Therapeutics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Karyopharm Therapeutics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.07M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $145.24M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $146.03M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $157.07M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $209.82M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $108.09M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $40.89M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $30.34M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.61M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $154.0K | Feb 28, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $47.0K | Mar 16, 2017 |
| FY2016 | Sep 30, 2016 | $48.0K | Mar 16, 2017 |
| FY2016 | Jun 30, 2016 | $59.0K | Mar 16, 2017 |
| FY2016 | Dec 31, 2015 | $25.0K | Mar 16, 2017 |
| FY2016 | Sep 30, 2015 | $75.0K | Mar 16, 2017 |
| FY2016 | Jun 30, 2015 | $150.0K | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | $16.0K | Mar 15, 2016 |
| FY2015 | Sep 30, 2014 | $21.0K | Mar 15, 2016 |
| FY2015 | Jun 30, 2014 | $21.0K | Mar 15, 2016 |
| FY2015 | Mar 31, 2014 | $171.0K | Mar 15, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($196.04M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($76.42M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($143.10M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($165.29M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($124.09M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($196.27M) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | ($199.59M) | Mar 1, 2022 |
| FY2018 | Dec 31, 2018 | ($58.21M) | Feb 28, 2019 |
| FY2018 | Sep 30, 2018 | ($48.08M) | Feb 28, 2019 |
| FY2018 | Jun 30, 2018 | ($33.66M) | Feb 28, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($90.71M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($119.44M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($129.54M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | ($142.20M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | ($98.27M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($171.85M) | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | ($189.28M) | Mar 1, 2022 |
| FY2018 | Dec 31, 2018 | ($57.46M) | Feb 28, 2019 |
| FY2018 | Sep 30, 2018 | ($49.15M) | Feb 28, 2019 |
| FY2018 | Jun 30, 2018 | ($34.33M) | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $108.42M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $164.42M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $240.44M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $358.17M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $305.31M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $313.05M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $294.96M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $341.19M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $180.29M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $180.39M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $401.34M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $350.44M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $376.64M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $374.83M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $384.98M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $262.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $245.19M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $158.02M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $50.83M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $18.14M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($292.93M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | ($186.02M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | ($136.21M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | ($16.66M) | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | ($79.67M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2020 | $50.55M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $49.77M | Feb 17, 2023 |
| FY2021 | Dec 31, 2018 | $183.17M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $129.46M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $162.24M | Feb 26, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (17) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | (9) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | (18) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (17) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | (18) | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | (2) | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 17, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.54M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $62.48M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $52.23M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $135.19M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $190.46M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $85.92M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $128.86M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $118.02M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $69.00M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $49.66M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $169.29M | Mar 1, 2022 |